Objective To evaluate the efficacy and safety of roxadustat in patients with refractory non-severe aplastic anemia(NSAA).Methods The clinical data of patients with refractory NSAA who had been treated with roxadustat continuously for at least 3 months and followed up for more than 6 months at Peking Union Medical College Hospital from October 2020 to August 2022 were retrospectively collected.The demographic information,clinical data,treatment efficacy,adverse reactions,and outcomes were evaluated,and the factors influencing efficacy were analyzed.Results A total of 41 patients were included.The male-to-female ratio was 16∶25,and the median age was 52(18-84)years.The median duration of roxadustat treatment was 5(3-20)months,and the median follow-up was 15(6-26)months.Hematologic improvement-erythroid(HI-E)was 12.2％,29.3％,46.3％,43.9％,and 30.3％at 1,2,3,6,and 12 months,respectively.The rate of transfusion independence was 28.5％,38.1％,and 33.3％at 3,6,and 12 months,respectively.Hemoglobin returned to normal in some patients after treatment with roxadustat.The incidence of adverse events was 22％,all of which were grade Ⅰ-Ⅱ and recoverable.No factors that could affect HI-E were identified.By the end of follow-up,45％of the patients relapsed,with a median time to relapse of 7(3-12)months.No clonal evolution was observed,and one patient died.Conclusion Roxadustat effectively improved anemia with good tolerance in patients with refractory NSAA.
NETL
NSTL
维普
万方数据
